Merck (MRK) Stock Could Trade Below Fair Value Despite Rich Earnings

Merck stock has surged over recent years, yet the valuation signals are mixed, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to undervaluation while market based multiples screen the shares as expensive. For investors, that split raises questions about how much of Merck’s pipeline and new product potential is already reflected in the price.

• Over the past 5 years Merck has delivered a total return of 141.2%, which puts recent valuation concerns in the context of a strong run for the stock.
• The approval of LIPFENDRA as the first FDA approved oral PCSK9 inhibitor may support expectations for future cash flows, while any setback in adoption or competitive pressure from other oral PCSK9 candidates could weigh on what investors are willing to pay.
• Merck scores 2 out of 6 on broader valuation checks, which leans expensive rather than a clear bargain.

The issue now is whether Merck’s recent gains and product momentum leave enough potential upside relative to its intrinsic value estimate to justify the current valuation.

Spot opportunities beyond Merck by reviewing hand picked healthcare and quality focused stocks in the solid balance sheet and fundamentals stocks screener (53 results).

Is Merck a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here uses projected free cash flows to estimate what Merck might be worth today. Merck generated last twelve month free cash flow of about $16.1b, and the model assumes these cash flows continue to grow rather than shrink over the next decade, then settle into a slower phase.

On those assumptions, the DCF model points to an intrinsic value of about $233 per share. Compared with the current share price, this implies the stock screens around 34.6% undervalued. Because LIPFENDRA is the first FDA approved oral PCSK9 inhibitor, the market focus on this product and rival oral PCSK9 candidates helps explain why investors are closely scrutinising whether the projected cash flows are realistic.

On balance, the Discounted Cash Flow valuation suggests Merck stock appears undervalued relative to the current market price.

Our Discounted Cash Flow (DCF) analysis suggests Merck is undervalued by 34.6%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Merck.

Has Merck Run Too Far on Earnings?

P/E is a useful cross check for Merck because earnings still anchor how most investors compare large pharmaceutical stocks. Merck currently trades on a P/E of about 118.5x, which is far above the pharmaceuticals industry average of 16.5x and also above the peer group average of 30.9x.

The fair P/E ratio implied by this model is 48.8x. That is already higher than the industry benchmark yet still well below where Merck trades today. This suggests that the shares screen as overvalued on earnings relative to what its growth, margins and risk profile would usually support.

On this P/E multiple, Merck stock appears overvalued compared with both its industry and the modelled fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

The Merck Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Merck pick up where this valuation split leaves off and explain what would need to happen to Merck's future growth, margins and earnings for the stock to be worth materially more or less than today's price on the Community page. Each one links its number to a clear view on how Merck's growth, profitability and risks might evolve, which you can revisit as new information emerges.

Merck investors are weighing two sharply different storylines that hinge on how the pipeline offsets patent and pricing risks.

Bull case: 18% undervalued

"Breakthroughs in biotechnology and biomarker-driven precision medicine are accelerating Merck's R&D productivity, with a record number of registrational trials and novel mechanisms under development..."

Read the full Bull Case to see why Merck could be undervalued

Bear case: 11% overvalued

"The eventual loss of exclusivity (LOE) for KEYTRUDA could lead to significant revenue decline if the pipeline doesn't compensate for this gap..."

Read the full Bear Case to see why Merck could be overvalued

Do you think there's more to the story for Merck? Head over to our Community to see what others are saying!

The Bottom Line

For Merck, the Discounted Cash Flow (DCF) model points to meaningful upside based on projected cash flows, while the rich P/E multiple signals the stock screens as overvalued on earnings. That gap reflects different emphases. Intrinsic value hinges on how efficiently Merck converts its current portfolio and pipeline into cash over time. In contrast, the market multiple leans on growth expectations and sentiment around key products. With broader valuation checks still weak, the key question is whether cash flows from LIPFENDRA and the wider pipeline ultimately justify the current earnings multiple or if the market is already paying up for that outcome.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com